PAFAH1B3 and neoplasm: In conclusion, our data highlighted PAFAH1B3 as a potential prognostic biomarker in LUAD, pointing to its dual signature of high expression in tumor tissues and pronounced exosomal release as a harbinger of poor patient prognosis.